Friday, September 22, 2017 2:00:11 PM
H2theIzzo,
I am just guessing but I expect there will be some news even if it is not top line results. This last raise won't last long and price moving news is definately needed. Linda will be talking about how to succeed in the midst of a competitive environment. A blinded review of what is currently known about the Phase 3 trial by an investigator from Kings College coupled with an explanation why there may be synergies with other treatments at crossover might go a long way to explain how time can play a critical or even deciding factor with regard to success or failure of a trial. Linda could then also share the impact of reimbursement considerations and other aspects of product development that have not been well explained or understood by many investors. Beyond this I think the attacks that NWBO has suffered will be mentioned by Linda as part of what should be expected by a small bio that intends to survive under the direction of original leadership and how NWBO has been able to do this. Based on various clues we have seen mentioned on this board I would expect a mention of the investigation and hints of the impact it might be having to date during this part of her presentation. I also expect a progress report of sorts will highlight many or most of the 10 things flipper44 has mentioned in his points for consideration. Best wishes.
I am just guessing but I expect there will be some news even if it is not top line results. This last raise won't last long and price moving news is definately needed. Linda will be talking about how to succeed in the midst of a competitive environment. A blinded review of what is currently known about the Phase 3 trial by an investigator from Kings College coupled with an explanation why there may be synergies with other treatments at crossover might go a long way to explain how time can play a critical or even deciding factor with regard to success or failure of a trial. Linda could then also share the impact of reimbursement considerations and other aspects of product development that have not been well explained or understood by many investors. Beyond this I think the attacks that NWBO has suffered will be mentioned by Linda as part of what should be expected by a small bio that intends to survive under the direction of original leadership and how NWBO has been able to do this. Based on various clues we have seen mentioned on this board I would expect a mention of the investigation and hints of the impact it might be having to date during this part of her presentation. I also expect a progress report of sorts will highlight many or most of the 10 things flipper44 has mentioned in his points for consideration. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
